In a sign of growing support for its immunotherapeutic approach to treat cancer, Dutch biotech ISA Pharmaceuticals B.V. has received a €26m money injection from new and existing investors, including US partner Regeneron Pharmaceuticals, Inc.. which used the round to lift its equity stake further in the private Netherlands-based company.
Regeneron Lifts Stake In Biotech Partner ISA Pharma
Equity Injection Part Of €26m Funding To Advance ISA’s Pipeline
Armed with €26m in fresh funds from investors that include partner Regeneron, ISA Pharma can now advance promising preclinical assets generated from its proprietary platform, containing a mix of synthetic antigenic peptides, its CEO tells Scrip.
